AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32659641 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous rectus fascia pubovaginal sling surgery (Group I)
Number of subjects: 30
Study 32659641 — intervention group
Group type: COMPARATOR
Intervention: Synthetic transobturator vaginal tape procedure (Group II)
Number of subjects: 30
Study 35793528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne (TB) rapid maxillary expander
Number of subjects: 52
Study 35793528 — intervention group
Group type: COMPARATOR
Intervention: Tooth bone-borne (TBB) rapid maxillary expander
Number of subjects: 52
Study 35793528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TB and TBB groups
Number of subjects: 52
Study 33648863 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education intervention
Number of subjects: 117
Study 36414488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (meditation, cognitive training, exercise, and nutrition counseling)
Number of subjects: 209
Study 36414488 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 209
Study 34075875 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 9803
Study 34075875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 9803
Study 34075875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls prevention
Number of subjects: 9803
Study 32561824 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (Ex, n=28)
Number of subjects: 40
Study 32561824 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n=12)
Number of subjects: 40
Study 33073599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-lockdown (pre-LD) period
Number of subjects: 137
Study 33073599 — intervention group
Group type: COMPARATOR
Intervention: During lockdown (LD) period
Number of subjects: 137
Study 33073599 — intervention group
Group type: COMPARATOR
Intervention: Non-PVD related RRD
Number of subjects: 137
Study 33073599 — intervention group
Group type: COMPARATOR
Intervention: PVR presence
Number of subjects: 137
Study 33444455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-Valve-Guedel Adaptor (BVGA)
Number of subjects: 25
Study 33444455 — intervention group
Group type: COMPARATOR
Intervention: Face Mask
Number of subjects: 25
Study 36145195 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake in early pregnancy
Number of subjects: 103
Study 36145195 — intervention group
Group type: EXPERIMENTAL
Intervention: Food sources of choline
Number of subjects: 103
Study 35221361 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP) for MH
Number of subjects: 0
Study 35221361 — intervention group
Group type: COMPARATOR
Intervention: Pectoral nerve block-II (PEC-II) for MRM
Number of subjects: 0
Study 35565859 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate (ACC) supplementation (2000 mg per day)
Number of subjects: 30
Study 35565859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study 35565859 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate (ACC)
Number of subjects: 30
Study 33371744 — intervention group
Group type: EXPERIMENTAL
Intervention: High RID (Risk Information Detail) video messages about anorexia
Number of subjects: 419
Study 33371744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RID video messages about anorexia
Number of subjects: 419
Study 33371744 — intervention group
Group type: COMPARATOR
Intervention: Control video about vaccination
Number of subjects: 419
Study 32835498 — intervention group
Group type: EXPERIMENTAL
Intervention: 47 g/kg sunflower meal (SFM)
Number of subjects: 480
Study 32835498 — intervention group
Group type: EXPERIMENTAL
Intervention: 97 g/kg sunflower meal (SFM)
Number of subjects: 480
Study 32835498 — intervention group
Group type: COMPARATOR
Intervention: Control diet (corn and soybean meal, 30 g/kg crude fibre)
Number of subjects: 480
Study 34333146 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Number of subjects: 31
Study 34333146 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TAA)
Number of subjects: 31
Study 35426485 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed biological therapies
Number of subjects: 0
Study 35426485 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy with first- and second-line drugs
Number of subjects: 0
Study 32758672 — intervention group
Group type: EXPERIMENTAL
Intervention: Role reversal after role-playing
Number of subjects: 36
Study 32758672 — intervention group
Group type: COMPARATOR
Intervention: Role-playing twice
Number of subjects: 36
Study 35410252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video promoting help-seeking
Number of subjects: 0
Study 35410252 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 0
Study 33866222 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived descriptive norms and willingness to drink
Number of subjects: 1062
Study 33866222 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol prototype similarity and alcohol-related perceived vulnerability
Number of subjects: 1062
Study 33184931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg for six weeks
Number of subjects: 4775
Study 33184931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan AUC increase
Number of subjects: 4775
Study 33184931 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patients compared to Black patients
Number of subjects: 4775
Study 34127610 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel training (twice weekly squat and calf raise exercises for 6 weeks)
Number of subjects: 19
Study 34127610 — intervention group
Group type: COMPARATOR
Intervention: Control group (time-matched control period)
Number of subjects: 19
Study 32444540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 28
Study 32444540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36480811 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib (80 mg BID) with moderate CYP3A inhibitors fluconazole and diltiazem
Number of subjects: 26
Study 36480811 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib (80 mg QD) with strong CYP3A inhibitor voriconazole
Number of subjects: 26
Study 36480811 — intervention group
Group type: COMPARATOR
Intervention: zanubrutinib (320 mg QD)
Number of subjects: 26
Study 36480811 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 26
Study 34020388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 25
Study 34020388 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual standard of care)
Number of subjects: 25
Study 32745254 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model (random forest) for predicting progression-free survival (PFS)
Number of subjects: 104758
Study 32745254 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model (random forest) for predicting overall survival (OS)
Number of subjects: 104758
Study 34736768 — intervention group
Group type: EXPERIMENTAL
Intervention: YYD302
Number of subjects: 184
Study 34736768 — intervention group
Group type: COMPARATOR
Intervention: Synovian
Number of subjects: 184
Study 34275349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 2000
Study 33583887 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training for 8 weeks
Number of subjects: 53
Study 33583887 — intervention group
Group type: COMPARATOR
Intervention: Control period (no IHG training)
Number of subjects: 53
Study 33082194 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every 4 weeks
Number of subjects: 108
Study 33082194 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod 0.5 mg once daily
Number of subjects: 108
Study 34983284 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing group
Number of subjects: 40
Study 34983284 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery group
Number of subjects: 40
Study 33812035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CSFD
Number of subjects: 3406
Study 33812035 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic CSFD
Number of subjects: 3406
Study 36977990 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear-interaction model
Number of subjects: 4250
Study 36977990 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted cubic splines model
Number of subjects: 4250
Study 36977990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive approach using Akaike's Information Criterion
Number of subjects: 4250
Study 33661781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (group OC)
Number of subjects: 120
Study 33661781 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 120
Study 33661781 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (group OP)
Number of subjects: 120
Study 32499503 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 60
Study 32499503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34050914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ultrasound performed by emergency physicians
Number of subjects: 103
Study 34050914 — intervention group
Group type: COMPARATOR
Intervention: Routine assessment (control group)
Number of subjects: 103
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: General knowledge of IPV among respondents
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence assessment relevance
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: History of IPV awareness training
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of IPV prevalence in practice
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of active IPV victims
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of IPV victims throughout careers
Number of subjects: 95
Study 34538458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic guidelines for detection or management of IPV
Number of subjects: 95
Study 35078853 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly durvalumab 1500 mg plus 3-weekly doublet chemotherapy (cisplatin 75 mg/m2 or carboplatin, AUC 5 and pemetrexed 500 mg/m2) for 4-6 cycles, followed by 4-weekly durvalumab 1500 mg until disease progression, unacceptable toxicity or patient withdrawal
Number of subjects: 480
Study 35078853 — intervention group
Group type: COMPARATOR
Intervention: Doublet chemotherapy alone for 4-6 cycles, followed by observation
Number of subjects: 480
Study 33238010 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rehabilitation program (application) along with traditional physical therapy (PT)
Number of subjects: 48
Study 33238010 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (PT)
Number of subjects: 48
Study 34779221 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐ICD
Number of subjects: 849
Study 34779221 — intervention group
Group type: COMPARATOR
Intervention: TV‐ICD
Number of subjects: 849
Study 33271428 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 33271428 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 0
Study 33271428 — intervention group
Group type: COMPARATOR
Intervention: GLP1 receptor agonists (GLP1RA)
Number of subjects: 0
Study 35149638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy support (counseling, relaxation, mindfulness-based exercises)
Number of subjects: 90
Study 35149638 — intervention group
Group type: COMPARATOR
Intervention: Standard care and educational videos (Control)
Number of subjects: 90
Study 34153415 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of moderate intensity aerobic exercise
Number of subjects: 2
Study 34153415 — intervention group
Group type: COMPARATOR
Intervention: Cognitively engaging control condition
Number of subjects: 2
Study 36232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied intervention
Number of subjects: 0
Study 36232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered online by therapists
Number of subjects: 0
Study 33810808 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml pomegranate juice and standard of care hospital treatment for COVID-19
Number of subjects: 48
Study 33810808 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo containing 500 ml of red water and standard of care hospital treatment for COVID-19
Number of subjects: 48
Study 36087608 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 1171
Study 36087608 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 1171
Study 32093783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (TRIPSS)
Number of subjects: 632
Study 32093783 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (JOQUER)
Number of subjects: 632
Study 32093783 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (TEARS)
Number of subjects: 632
Study 32093783 — intervention group
Group type: COMPARATOR
Intervention: 5-year follow-up of ASSESS cohort
Number of subjects: 632
Study 34850000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 245
Study 33393402 — intervention group
Group type: EXPERIMENTAL
Intervention: LoSenseT protocol (sensorimotor training for lower limbs)
Number of subjects: 20
Study 32697335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus low-dose cytarabine (LDAC)
Number of subjects: 116
Study 32697335 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 116
Study 616484402 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Smoking Cessation Intervention
Number of subjects: 0
Study 33601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Pictorial Warning Labels (PWLs)
Number of subjects: 169
Study 33601986 — intervention group
Group type: COMPARATOR
Intervention: Non-narrative Pictorial Warning Labels (PWLs)
Number of subjects: 169
Study 33601986 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 169
Study 34527079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONSs) with a high‐protein–high‐calorie mixture containing immunonutrients (Impact)
Number of subjects: 0
Study 34527079 — intervention group
Group type: COMPARATOR
Intervention: Standard high‐calorie–high‐protein nutritional blends
Number of subjects: 0
Study 35618939 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O2 priming (2%)
Number of subjects: 3
Study 35618939 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 3
Study 34671668 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness service intervention
Number of subjects: 183
Study 34671668 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral recruitment through media sources
Number of subjects: 183
Study 34671668 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 183
Study 34671668 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal survey
Number of subjects: 183
Study 32706731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile version of the ASES questionnaire
Number of subjects: 50
Study 32706731 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the ASES questionnaire
Number of subjects: 50
Study 35401736 — intervention group
Group type: EXPERIMENTAL
Intervention: Single channel electroencephalogram (EEG) approach through visual‐motor activity
Number of subjects: 0
Study 35401736 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study 32293119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of trans-capsaicin
Number of subjects: 0
Study 32293119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36364934 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB + D (3 g Calcium HMB + 2000 IU D per day)
Number of subjects: 43
Study 36364934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 33106185 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 118
Study 33106185 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 118
Study 35315305 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 30
Study 35315305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 33982872 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg tablet daily for 12 weeks
Number of subjects: 164
Study 33982872 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 164
Study 33982872 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg tablet
Number of subjects: 164
Study 33982872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 32860406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after PPCI
Number of subjects: 375
Study 32860406 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 375
Study 32860406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs)
Number of subjects: 375
Study 35198913 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive focal mass drug administration (rfMDA)
Number of subjects: 0
Study 35198913 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive vector control (RAVC)
Number of subjects: 0
Study 35198913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rfMDA plus RAVC
Number of subjects: 0
Study 35198913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sero-prevalence as an endpoint
Number of subjects: 0
Study 35198913 — intervention group
Group type: COMPARATOR
Intervention: Quantitative polymerase chain reaction (qPCR) prevalence
Number of subjects: 0
Study 33916192 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation comprising Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0918 at a daily dose of 10^9 bacteria for three months.
Number of subjects: 151
Study 33916192 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months.
Number of subjects: 151
Study 34612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Online
Number of subjects: 528
Study 34612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimming World Online
Number of subjects: 528
Study 34612589 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Weight Loss Plan
Number of subjects: 528
Study 34612589 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 528
Study 32448624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination during pregnancy
Number of subjects: 118
Study 32448624 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers vaccinated after delivery)
Number of subjects: 118
Study 32448624 — intervention group
Group type: EXPERIMENTAL
Intervention: Post booster vaccinations
Number of subjects: 118
Study 34233065 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI)
Number of subjects: 2378
Study 34507046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 50
Study 34507046 — intervention group
Group type: COMPARATOR
Intervention: Sham-Dry Needling (Sham-DN)
Number of subjects: 50
Study 34931478 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplantation (FMT), 4 FMTs each 2 weeks apart after 2 placebo transplantations.
Number of subjects: 9
Study 32173916 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks
Number of subjects: 66
Study 32173916 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 or 200 mg
Number of subjects: 66
Study 32173916 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 35675561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Mini Dental Implants (2MDI)
Number of subjects: 37
Study 35675561 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Mini Dental Implants (4MDI)
Number of subjects: 37
Study 35675561 — intervention group
Group type: COMPARATOR
Intervention: 2 Conventional Dental Implants (2CDI)
Number of subjects: 37
Study 33731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals with Advanced Online Publication (AOP)
Number of subjects: 25
Study 33731261 — intervention group
Group type: COMPARATOR
Intervention: Journals without Advanced Online Publication (AOP)
Number of subjects: 25
Study 33731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall publication speed
Number of subjects: 25
Study 33731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Impact Factor (IF) and Article Processing Charges (APCs)
Number of subjects: 25
Study 33731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of IF
Number of subjects: 25
Study 35927547 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored educational website (CHiCOS)
Number of subjects: 1294
Study 35927547 — intervention group
Group type: COMPARATOR
Intervention: Untailored information derived from the Vaccine Information Sheet (VIS)
Number of subjects: 1294
Study 35927547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tailored and untailored combined
Number of subjects: 1294
Study 33400099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg daily (weight-based dosing)
Number of subjects: 80
Study 33400099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 80
Study 32338940 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-inclusive vulnerability discussions
Number of subjects: 82
Study 32338940 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-exclusive vulnerability discussions
Number of subjects: 82